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Abstract Peroxisome proliferator-activated receptors (PPARs)
are members of the nuclear receptor superfamily. They are
divided into three subtypes (K, L or N, and Q) and are involved in
lipid and glucose homeostasis and in the control of inflammation.
In this study, we analyzed the expression of PPARs in murine
dendritic cells (DCs), the most potent antigen presenting cells.
We find that immature as well as mature spleen-derived DCs
express PPARQ, but not PPARK, mRNA and protein. We also
show that the PPARQ activator rosiglitazone does not interfere
with the maturation of DCs in vitro nor modifies their ability to
activate naive T lymphocytes in vivo. Finally, we present evidence
that PPARQ activators down-modulate the CD40-induced
secretion of interleukin-12, a potent Th1-driving factor. These
data suggest a possible role for PPARQ in the regulation of
immune responses. ß 2000 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
Key words: Dendritic cell ;
Peroxisome proliferator-activated receptor; Interleukin-12
1. Introduction
Peroxisome proliferator-activated receptors (PPARs) are li-
gand-activated transcription factors belonging to the nuclear
receptor family [1]. They are activated by a variety of com-
pounds including hypolipidemic and insulin-sensitizing drugs
as well as natural fatty acids and their eicosanoid metabolites
[2]. PPARs function as regulators of lipid and lipoprotein
metabolism, glucose homeostasis, cellular di¡erentiation and
also appear to control the in£ammatory response [3,4]. In
addition to regulating gene transcription through the peroxi-
some proliferator-responsive element, it has recently been
demonstrated that PPARs negatively interfere with NF-UB,
AP-1 and STAT signaling pathways [5^10]. To date, three
subtypes of PPARs, which are characterized by distinct tissue
distribution patterns, have been described in humans and ro-
dents: PPARK, L (N) and Q. PPARK is highly expressed in
cells with high catabolic rates of fatty acids [11,12]. PPARL
(N) is ubiquitously expressed [12,13] whereas PPARQ has a
more restricted expression [3]. Along with its expression in
adipocyte tissue, colonic mucosa [14] and the vascular wall
[15,16], PPARQ has also been shown to be expressed in the
spleen white pulp and Peyer’s patches [13,17], organs mainly
composed of B and T lymphocytes and of dendritic cells
(DCs). This tissue-speci¢c location, as well as its expression
in monocytes/macrophages [5,6,18^20] and in B [21] and T
lymphocytes [22^24] raise the possibility that PPARQ could
be involved in innate/adaptive immunity. This speculation is
reinforced by the demonstration that PPAR members may act
as important immunomodulatory mediators both in vitro and
in vivo [5^7,25]. In this report, we investigated the possibility
that PPARs may be expressed and may regulate immuno-
stimulatory functions of DCs, for instance by reducing the
expression of certain genes involved in T cell sensitization.
DCs are the most potent professional antigen presenting
cells (APCs) capable of inducing T cell-mediated immune re-
actions against a wide range of antigens, including chemical
haptens, foreign proteins, infectious agents and tumor-associ-
ated antigens [26,27]. This unique property is due to their
ability to capture, process and present antigens to naive T
lymphocytes in the secondary lymphoid tissues [28]. In re-
sponse to signals delivered by DCs, T lymphocytes di¡eren-
tiate into type 1 (interleukin (IL)-2, IFNQ) or type 2 (IL-4, IL-
5, IL-10) cytokine-producing cells which in turn orientate the
immune response towards a cellular or humoral response,
respectively. In most tissues, following internalization and
processing of exogenous antigens, immature DCs undergo a
process of maturation which is a crucial step in their develop-
ment into fully potent APCs. They increase their expression of
MHC class II molecules as well as costimulatory molecules
(CD40, CD54, CD80, CD86,) which are necessary to deliver
accessory signals required for T cell activation [29,30]. DCs
also upregulate their production of T cell-stimulatory cyto-
kines. During antigen-speci¢c interaction between DCs and
naive T lymphocytes, CD40/CD40L ligation induces the syn-
thesis of IL-12 by DCs that in turn mediates the di¡erentia-
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tion of naive T helper (Th) cells to IFNQ-producing cells [31^
34]. The demonstration that PPAR activators may regulate
the synthesis of cytokines and/or surface molecules by various
cell types [5^7] raised the possibility that members of the
PPAR family could also modulate the expression of costimu-
latory molecules and/or cytokines by maturing DC and fur-
ther in£uence their function. In this report, we investigated
the expression of PPARs in murine splenic DCs by reverse
transcriptase-polymerase chain reaction (RT-PCR), Western
blot and immunocytochemistry. Our results indicate that
PPARQ is expressed in DCs whereas PPARK appears to be
absent. We also determined the e¡ects of PPARQ activators on
maturation and accessory function of DCs. We show that
PPARQ activation does not a¡ect the maturation of DCs
nor their ability to sensitize naive T lymphocytes in vivo.
Interestingly, we found that PPARQ agonists signi¢cantly re-
duce the CD40-induced synthesis of IL-12 by DCs, suggesting
a role for PPARQ in the orientation of immune responses.
2. Materials and methods
2.1. Reagents and antibodies (Abs)
All reagents were purchased from Sigma (St. Quentin-Fallavier,
France) unless otherwise indicated. 15-Deoxy-v12;14-prostaglandin J2
(15d-PGJ2) was from Cayman Chemical (Ann Arbor, MI, USA).
Rosiglitazone (RSG) was kindly provided by Dr. A. Bril (SmithKline
Beecham, Rennes, France). A⁄nity-puri¢ed rabbit polyclonal Abs
speci¢c for PPARQ have already been described [19]. A⁄nity-puri¢ed
rabbit Abs directed against an irrelevant parasite antigen were pre-
pared in the laboratory and were used as a negative control. FITC-
conjugated anti-CD80 (clone 16-10A1, hamster IgG), -CD86 (clone
GL1, rat IgG2a), -CD40 (3/23, rat IgG2a), biotin-conjugated anti-
CD11c (HL3, hamster IgG) and -CD54 (3E2, hamster IgG) Abs
were purchased from Becton Dickinson (Le Pont de Claix, France).
The anti-MHC class II hybridoma (M5/114, rat IgG2b) was kindly
provided by Dr. Ann Ager (NIMR, Mill Hill, UK). FITC-conjugated
goat anti-rat IgG (Beckman Coulter, Villepinte, France), FITC-con-
jugated donkey F(abP)2 anti-rabbit Igs and FITC-streptavidin (FITC-
SA) (Clinisciences, Montrouge, France) were used as second stage
reagents. Anti-CD11c-conjugated microbeads (Miltenyi Biotech,
Paris, France) were used for MACS puri¢cation of DCs. Mouse re-
combinant GM-CSF was purchased from Biosource (Nivelles, Bel-
gium). Human recombinant Flt-3 ligand was from Immunex Corp.
(Seattle, WA, USA).
2.2. Preparation and treatment of DCs
DCs were isolated from spleens obtained from Flt-3 ligand injected
C57BL/6 mice as already described [35]. Brie£y, spleens were digested
with collagenase for 30 min at 37‡C and then dissociated in RPMI
containing 10 mM EDTA. The cell suspension was separated into low
and high density fractions on a Nycodenz gradient (Nycomed Phar-
ma, Oslo, Norway) (1700Ug for 15 min). Splenic DCs were collected
at the interface, washed twice with RPMI and puri¢ed by positive
selection over two successive MACS columns by using anti-CD11c-
conjugated microbeads. After puri¢cation, the cells were plated in 100
mm Petri dishes for 2 h at 37‡C in RPMI supplemented with 2%
ultroser (Life Technologies, Cergy Pontoise, France), a serum free
medium supplement. Non-adherent cells were removed by vigorous
pipetting and the adherent cells (immature DCs) were allowed to
mature for 18 h in RPMI supplemented with 2% ultroser and 10
ng/ml of GM-CSF in the presence or in the absence of 10 WM
RSG. In general, non-adherent mature DCs represented at least
99% of the total cell population as assessed by FACS analysis with
anti-CD11c monoclonal Ab. For pulse experiments, 50 Wg/ml keyhole
limpet hemocyanin (KLH) was added (pulsed DCs) or not (unpulsed
DCs) to immature DCs for 18 h as reported [35] in the presence or not
of RSG.
2.3. Immunization protocol and in vitro assays
After overnight culture, non-adherent unpulsed or KLH-pulsed
DCs were collected, washed and administered at a dose of 3U105
cells into the hind footpads of syngeneic mice. Five days later, pop-
liteal lymph node (LN) cells (5U105 cells/well in a £at-bottom 96-well
plate) were cultured in Click’s medium supplemented with 0.5% nor-
mal mouse serum and various concentrations of KLH for 4 days at
37‡C. During the last 18 h, 0.5 WCi of [3H]thymidine per well was
added. At 72 h time point, IFNQ, IL-4, IL-5 and IL-10 production
were measured in the culture supernatants from LN cells by enzyme-
linked immunosorbent assay (ELISA). IL-4, IL-5 and IL-10 were
quanti¢ed by two-site ELISA adapted from Pharmingen protocols
(Becton Dickinson). The supernatant was assayed for IFNQ using
an ELISA kit from RpD Systems (Abingdon, UK).
2.4. RNA extraction and RT-PCR analysis
Total RNA from DCs was obtained using the TRIzol reagent (Life
Technologies, Grand Island, NY, USA) and reverse-transcribed using
random hexamer primers and Superscript reverse transcriptase (Life
Technologies). Ampli¢cation by PCR was performed with the follow-
ing primers: PPARK, 5P-CCAAGTCACCTTGCTAAAGTAC-3P and
5P-GGTGTCATCTGGATGGTTGCTC-3P (fragment size 320 bp);
PPARQ, 5P-GTCCATGAGATCATCTACACG-3P and 5P-GTGCT-
CTGTGACGATCTGCCT-3P (fragment size 376 bp). L-Actin-speci¢c
primers 5P-TCACCGAGGCCCCCCTGAAC-3P and 5P-GCACGC-
ACTGTAATTCCTC-3P were used as control (fragment size 324
bp). The numbers of PCR cycles selected were as follows: PPARK
(36), PPARQ (36) and L-actin (30).
2.5. Western blot and immunocytochemistry analysis
Total protein was extracted from DCs with sodium dodecyl sulfate
(SDS) sample bu¡er, resolved by SDS^PAGE and transferred to ni-
trocellulose ¢lters. Proteins were analyzed by Western blot with a⁄n-
ity-puri¢ed rabbit anti-PPARQ Abs and horseradish peroxidase-la-
belled goat anti-rabbit Ig (Sano¢ Diagnostics Pasteur, Marnes,
France). Speci¢city of anti-PPARQ Abs was checked by Western
blot analysis using in vitro synthesized PPARQ protein [19]. Immuno-
£uorescence staining was performed as previously described [19].
Brie£y, immature DCs cultured for 2 h on gelatin-coated coverslips
were ¢xed in 2% paraformaldehyde in phosphate-bu¡ered saline
(PBS) (pH 7.4) for 10 min and permeabilized with cold acetone/meth-
anol (1:1) for 5 min. After incubation with anti-PPARQ Abs or the
control Abs, proteins were visualized using secondary FITC-conju-
gated donkey F(abP)2 anti-rabbit Abs.
2.6. FACS analysis
Phenotypic analysis of DCs was performed with anti-MHC class II
hybridoma or biotin-conjugated anti-CD11c, -CD54 or FITC-conju-
gated anti-CD40, -CD80 and -CD86 Abs. Brie£y, 2U105 cells/well
were plated in 96-well plates, resuspended in 50 Wl of culture super-
natant or 20 Wl of FITC or biotin-conjugated primary Ab diluted in
PBS supplemented with 5% fetal calf serum and 0.2% NaN3 and
incubated on ice for 30 min. After washes, FITC-conjugated goat
anti-rat IgG or FITC-SA were added when needed for another 20
min, followed by three washes. After the last wash, cells were ¢xed
in 1% paraformaldehyde in PBS and were analyzed on a FACScalibur
£ow cytometer. Data were analyzed using CellQuest software (Becton
Dickinson).
2.7. Stimulation and measurement of IL-12 secretion
L cells transfected with the ligand for CD40 (CD40L) were used to
induce CD40 triggering on DCs. Non-transfected L cells were used for
control cultures. 105 immature DCs were incubated with 104 irradi-
ated (10 000 rad) CD40L-transfected L cells in the presence or absence
of di¡erent doses of RSG. After 24 h, supernatants were collected and
IL-12 p40 and IL-12 p70 concentrations were measured by ELISA
(RpD Systems).
3. Results
3.1. PPARQ, but not PPARK, is expressed in spleen-derived
DCs
To determine the expression of PPARs in DCs, we per-
formed RT-PCR and Western blot analysis on freshly isolated
(immature) and on overnight cultured (mature) DCs derived
from mouse spleen. RT-PCR analysis demonstrated the pres-
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ence of PPARQ, but not PPARK, mRNA in immature as well
as in mature DCs (99% pure) (Fig. 1A). Western blot analysis
using speci¢c Abs for PPARQ con¢rmed the presence of PPARQ
protein in mouse DCs (Fig. 1B). The identity of the detected
55 kDa band was con¢rmed by co-migration with a band
from in vitro produced PPARQ protein. We noted that PPARQ
expression was more pronounced in immature compared to
mature DCs. By contrast, consistent with RT-PCR analysis,
PPARK protein was undetectable in DCs (not shown). To
identify the subcellular location of PPARQ in DCs, indirect
immuno£uorescence analysis was performed. Staining with
anti-PPARQ Abs revealed immunoreactivity in the cytoplas-
mic compartment at the periphery of the nucleus, but not in
the dendrites (Fig. 1C).
3.2. PPARQ activation has no e¡ect on the maturation of DCs
in vitro
We then assessed the e¡ect of PPARQ activation on the
expression of cell surface molecules involved in APC function
on DCs undergoing maturation. To this end, immature DCs
were cultured for 18 h (the period necessary for spontaneous
in vitro DC maturation) in the presence of 10 WM of the
highly potent synthetic PPARQ activator RSG. First, we
checked that RSG did not induce cell death as already de-
scribed in the literature for numerous other cell types
[19,21,24,36,37]. Enumeration of cells excluding trypan blue
revealed that 90^95% of DCs were alive after a 18 h culture in
the presence or absence of RSG. DC staining with FITC-
Annexin V and propidium iodide con¢rmed that DCs did
not undergo apoptosis after RSG treatment (data not shown).
Afterwards, the expression of cell surface molecules was moni-
tored. As shown in Fig. 2, the overnight culture of immature
DCs induced their maturation characterized by an increased
expression of MHC class II molecules as well as the costimu-
latory molecules CD80, CD86, CD40 and CD54. Treatment
of immature DCs with RSG (10 WM) for 18 h did not modify
the phenotypic features of mature DCs. This suggests that
activation of PPARQ does not interfere with the maturation
of DCs in vitro nor alter the synthesis of surface molecules
known to participate in T cell activation and di¡erentiation.
3.3. PPARQ activation does not a¡ect the accessory function of
DCs in vivo
We then evaluated the e¡ect of RSG on the ability of DCs
pulsed in vitro with antigens to sensitize T cells in vivo. To
this end, DCs were pulsed with KLH during overnight culture
as previously reported [35] in the presence or absence of RSG.
After washing, DCs were injected into the hind footpads of
syngeneic mice and the popliteal LNs were harvested 5 days
later and restimulated in vitro with KLH. The data in Fig. 3
Fig. 1. Expression of PPARQ in murine splenic DCs. A: mRNA expression of PPARK and PPARQ as analyzed by RT-PCR. As positive con-
trols for PPAR mRNA expression, cDNA from mouse adipocyte tissue or from liver was used. B: Western blot analysis of PPARQ protein ex-
pression in DCs (5U106cells/lane). Western blots were probed with a⁄nity-puri¢ed rabbit anti-PPARQ Abs at 2 Wg/ml. The identity of the 55
kDa band is con¢rmed by co-migration with a band seen in in vitro produced PPARQ protein but not in the control in vitro translation prod-
ucts. The a⁄nity-puri¢ed rabbit Abs used as a negative control did not reveal any reactivity (not shown). Sizes are indicated in kDa. C: Immu-
nocytochemical analysis of PPARQ expression in DCs. Cultured DCs were stained with 10 Wg/ml of the a⁄nity-puri¢ed anti-PPARQ Abs or an
a⁄nity-puri¢ed rabbit Ab speci¢c for an irrelevant parasite antigen (control) (magni¢cation, U900).
FEBS 24411 11-12-00
C. Faveeuw et al./FEBS Letters 486 (2000) 261^266 263
indicate that administration of DCs pulsed ex vivo with KLH
resulted in T cell priming, as assessed by KLH-dependent
proliferation in culture. The proliferative response of LN cells
from mice injected with RSG-treated KLH-pulsed DCs was
identical suggesting that the T cell response was not altered.
We next analyzed the cytokines released by LN cells primed
with the di¡erent DC preparations in vivo. KLH-pulsed DCs
induced the activation of cells secreting IFNQ, IL-4, IL-5 and
IL-10. Similarly, RSG-treated KLH-pulsed DCs sensitized
cells produced equal quantities of IFNQ, IL-4, IL-5 and IL-
10. This suggests that PPARQ activation during the pulse step
does not a¡ect the APC function of DCs.
3.4. PPARQ activators reduce the CD40-induced secretion of
the Th1-promoting factor IL-12 in DCs
To further study the role of PPARQ in DC function, we
Fig. 2. E¡ects of the PPARQ activator RSG on the surface expression of MHC class II, CD80, CD86, CD40 and CD54 on DCs undergoing
maturation. Immature DCs were cultured in the presence or absence of RSG. After 18 h, untreated mature DCs and RSG-treated mature DCs
were stained with the indicated Abs and analyzed by £ow cytometry. The background represents DCs stained with the secondary Ab alone
(MHC class II) or FITC-SA (CD54) or unstained DCs (CD80, CD86 and CD40). One representative experiment out of seven is shown.
Fig. 3. E¡ect of RSG on the ability of KLH-pulsed DCs to prime T lymphocytes in vivo. Immature DCs were pulsed or not (unpulsed DCs)
extracorporally with 50 Wg/ml of KLH in the absence (KLH-pulsed DCs) or the presence (RSG-treated KLH-pulsed DCs) of RSG for 18 h.
Then, DCs were injected into the hind footpads of naive mice and 5 days later, draining LNs were harvested and cultured with various doses
of KLH. Cytokine production and proliferation were measured after 3 and 4 days of culture, respectively. Results represent the mean of tripli-
cate cultures þ S.D. One representative experiment out of ¢ve is shown.
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stimulated DCs to produce IL-12 in a CD40L-dependent
manner, a situation that occurs during the interactions be-
tween DCs and T lymphocytes. To this end, immature DCs
were incubated for 24 h with transfected cells expressing
CD40L in the presence or not of RSG and the production
of IL-12 was measured. Compared to DCs cultured with un-
transfected L-cells, CD40 ligation dramatically increased the
concentration of IL-12 p40 and of the bioactive heterodimer
IL-12 p70 in the DC culture supernatants (Fig. 4). Interest-
ingly, this induction was reduced, in a concentration-depen-
dent manner, by RSG. The maximal inhibitory activity was
achieved with RSG at 10 WM (72 þ 4% inhibition). In the same
manner, the CD40-induced synthesis of IL-12 by DCs was
reduced in the presence of the naturally occurring PPARQ
activator 15d-PGJ2 (80 þ 3% at 5 WM). Examination of IL-
12 p40 mRNA levels in DCs by RT-PCR indicated that the
inhibitory e¡ects of RSG on IL-12 synthesis probably occur
at the transcriptional level (not shown). These ¢ndings suggest
that activation of PPARQ in DCs may negatively regulate
expression of genes that are important in immune responses.
4. Discussion
Recent reports suggest that PPARQ may play a role in the
control of the in£ammatory response, particularly by a¡ecting
macrophage function [5,6,17^20]. For instance, PPARQ acti-
vation reduces the production of certain in£ammatory medi-
ators and cytokines in activated macrophages in response to a
variety of exogenous agents. This novel function for PPARQ
in modulating in£ammation prompted us to investigate the
possibility that PPARQ may be expressed and may regulate
gene expression in DCs, the most potent professional APCs.
Indeed, DCs have the unique capacity to prime and to educate
naive T lymphocytes. In these mechanisms, in£ammatory me-
diators and/or cytokines play a key role in initiating and po-
larizing the immune response.
In this report, we show for the ¢rst time that PPARQ, but
not PPARK, is expressed in murine DCs. Indeed, in freshly
isolated spleen-derived DCs (immature) as well as in mature
DCs, we found relatively high amounts of PPARQ principally
located in the cytoplasm around the nucleus. We also con-
¢rmed this ¢nding in the bone marrow-derived mouse DC line
DC2.4 (not shown) as well as in human monocyte-derived
DCs (P. Gosset, in preparation). Interestingly, this preferen-
tial cytoplasmic location in DCs di¡ers from that of PPARQ in
macrophages since, in these cells, it is located in the nucleus
[19,20]. On the other hand, in adipocyte [38] and in endothe-
lial cells [36] PPARQ is located principally in the cytoplasm.
We then assessed the e¡ects of PPARQ activation on DC
viability, maturation and function. Treatment of immature
DCs with the synthetic pharmacological compound RSG, an
anti-diabetic drug with high a⁄nity for PPARQ, for 18^24 h
did not a¡ect DC viability, unlike other cell types such as
macrophages [19], endothelial cells [36], astrocytes [37] and
B and T lymphocytes [21,24] where PPARQ agonists have
been shown to induce non-apoptotic or apoptotic cell death.
Since maturation is an essential process during which DCs
acquire optimal immunostimulatory properties, we examined
the in£uence of PPARQ activators on the expression of a
number of cell surface molecules known to be upregulated
during maturation. Our data show that DCs that have under-
gone maturation in vitro in the presence of RSG express the
same levels of MHC class II, CD80, CD86, CD40 and CD54
molecules compared to untreated mature DCs. Similarly, we
found that RSG does not modify the expression of costimu-
latory molecules on CD40-activated murine DCs (not shown).
We then evaluated the in£uence of PPARQ activation on the
ability of antigen-pulsed DCs to sensitize T cells in vivo. We
found that treatment of immature DCs with RSG did not
in£uence the antigen-speci¢c T cell response in terms of pro-
liferation and cytokine production. This suggests that PPARQ
activation in DCs undergoing maturation does not interfere
with the steps of antigen capture, processing and presentation
to naive T lymphocytes. We then studied whether PPARQ
activation may interfere with the CD40-mediated IL-12 induc-
tion in DCs. This mode of stimulation occurs in the LNs
during DC/T cell interactions and the subsequent IL-12 syn-
thesis by DCs is particularly important in the polarization of
the acquired immune response [31,32,34]. Our data show that
PPARQ activation by RSG or by the endogenous ligand 15d-
PGJ2, a PGD2 metabolite, decreases the production of IL-12
p40 and p70 in DCs stimulated via CD40/CD40L interaction.
Fig. 4. E¡ect of PPARQ activators on the secretion of IL-12 p40
and IL-12 p70 by CD40L-stimulated murine DCs. DCs were cul-
tured with L cells expressing or not CD40L for 24 h in the absence
or presence of increasing concentrations of RSG or with 15d-PGJ2
(¢nal concentration: 5 WM) or vehicle (DMSO). Cell viability was
not altered by the indicated treatments (data not shown). Results
are expressed as means þ S.D. of triplicates and are representative of
¢ve independent experiments. Data were statistically analyzed using
the Student’s t test and considered to be signi¢cant when P6 0.05
(compared to medium or to vehicle). Signi¢cant di¡erences are des-
ignated by *.
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It is therefore tempting to speculate that PPARQ activation in
DCs, for instance by endogenous fatty acid derivatives, may
play a role in the polarization of immune responses. At this
stage, it is important to mention that in our model of immu-
nization using pulsed DCs (Fig. 3), we could not test this
hypothesis since the PPARQ agonist was added during the
pulse step, but not during the antigen presentation step that
occurs during DC/T cell contact. In vivo experiments are
therefore warranted to test this assumption.
Although the role of certain prostanoids, particularly the
cAMP-elevating factor PGE2, in the negative control of IL-12
synthesis has already been demonstrated [39,40], our data
suggest that other members of the polyunsaturated fatty
acid family may also inhibit IL-12 production in DCs via
cAMP-independent pathway(s). In this study, we did not ex-
plore the mechanism by which PPARQ down-modulates IL-12
synthesis in DCs. However, since the NF-UB is the major
signaling pathway triggered by CD40^CD40L interaction
[41] and since activation of PPARQ has already been shown
to negatively interfere with the expression of a subset of genes
by antagonizing the NF-UB pathway [5,6,42,43], it is likely
that PPARQ activators inhibit IL-12 production in DCs by
interfering with NF-UB.
In conclusion, our data indicate that the nuclear hormone
receptor PPARQ is expressed in mouse DCs and that during
immune responses, PPARQ activation by endogenous fatty
acid-derived ligands may play a role in adaptive immunity
by a¡ecting the synthesis of the Th1-driving cytokine IL-12.
Acknowledgements: This work was supported by the INSERM and
the Pasteur Institute of Lille. C.F. and G.C. were recipients of the
post-doctoral fellowship from ‘la Fondation pour le Recherche Me¤d-
icale’. F.T. is a member of the CNRS. The authors greatly thank Dr.
A. Bril (SmithKline Beecham, Rennes, France) for the gift of RSG,
Dr. S. Lebecque (Schering-Plough, Dardilly, France) for CD40L-
transfected L cells and Prof. K.L. Rock (University of Massachusetts,
Worcester, MA, USA) and the Dana-Farber cancer Institute (Boston,
MA, USA) for the DC2.4 cell line.
References
[1] Mangelsdorf, D.J., Thummel, C., Beato, M., Herrlich, P., Schutz,
G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Cham-
bon, P. and Evans, R.M. (1995) Cell 83, 835^839.
[2] Krey, G., Braissant, O., L’Horset, F., Kalkhoven, E., Perroud,
M., Parker, M.G. and Wahli, W. (1997) Mol. Endocrinol. 11,
779^791.
[3] Lemberger, T., Desvergne, B. and Wahli, W. (1996) Annu. Rev.
Cell. Dev. Biol. 12, 335^363.
[4] Pineda Torra, I., Gervois, P. and Staels, B. (1999) Curr. Opin.
Lipidol. 10, 151^159.
[5] Jiang, C., Ting, A.T. and Seed, B. (1998) Nature 391, 82^86.
[6] Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J. and Glass, C.K.
(1998) Nature 391, 79^82.
[7] Staels, B., Koenig, W., Habib, A., Merval, R., Lebret, M., Torra,
I.P., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J.C., Najib,
J., Maclouf, J. and Tedgui, A. (1998) Nature 393, 790^793.
[8] Zhou, Y.C. and Waxman, D.J. (1999) J. Biol. Chem. 274, 2672^
2681.
[9] Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W.,
Peters, J.M., Gonzalez, F.J., Fruchart, J.C., Tedgui, A., Haege-
man, G. and Staels, B. (1999) J. Biol. Chem. 274, 32048^32054.
[10] Delerive, P., Martin-Nizard, F., Chinetti, G., Trottein, F., Fru-
chart, J.C., Najib, J., Duriez, P. and Staels, B. (1999) Circ. Res.
85, 394^402.
[11] Issemann, I. and Green, S. (1990) Nature 347, 645^650.
[12] Braissant, O., Foufelle, F., Scotto, C., Dauca, M. and Wahli, W.
(1996) Endocrinology 137, 354^366.
[13] Braissant, O. and Wahli, W. (1998) Endocrinology 139, 2748^
2754.
[14] Mansen, A., Guardiola-Diaz, H., Rafter, J., Branting, C. and
Gustafsson, J.A. (1996) Biochem. Biophys. Res. Commun. 222,
844^851.
[15] Marx, N., Schonbeck, U., Lazar, M.A., Libby, P. and Plutzky, J.
(1998) Circ. Res. 83, 1097^1103.
[16] Marx, N., Bourcier, T., Sukhova, G.K., Libby, P. and Plutzky, J.
(1999) Arterioscler. Thromb. Vasc. Biol. 19, 546^551.
[17] Greene, M.E., Blumberg, B., McBride, O.W., Yi, H.F., Kron-
quist, K., Kwan, K., Hsieh, L., Greene, G. and Nimer, S.D.
(1995) Gene Expr. 4, 281^299.
[18] Tontonoz, P., Nagy, L., Alvarez, J.G., Thomazy, V.A. and
Evans, R.M. (1998) Cell 93, 241^252.
[19] Chinetti, G., Griglio, S., Antonucci, M., Torra, I.P., Delerive, P.,
Majd, Z., Fruchart, J.C., Chapman, J., Najib, J. and Staels, B.
(1998) J. Biol. Chem. 273, 25573^25580.
[20] Marx, N., Sukhova, G., Murphy, C., Libby, P. and Plutzky, J.
(1998) Am. J. Pathol. 153, 17^23.
[21] Padilla, J., Kaur, K., Harris, S.G. and Phipps, R.P. (2000) Ann.
N.Y. Acad. Sci. 905, 97^109.
[22] Clark, R.B., Bishop-Bailey, D., Estrada-Hernandez, T., Hla, T.,
Puddington, L. and Padula, S.J. (2000) J. Immunol. 164, 1364^
1371.
[23] Yang, X.Y., Wang, L.H., Chen, T., Hodge, D.R., Resau, J.H.,
DaSilva, L. and Farrar, W.L. (2000) J. Biol. Chem. 275, 4541^
4544.
[24] Harris, S.G. and Phipps, R.P. (2000) Ann. N.Y. Acad. Sci. 905,
297^300.
[25] Devchand, P.R., Keller, H., Peters, J.M., Vazquez, M., Gonzalez,
F.J. and Wahli, W. (1996) Nature 384, 39^43.
[26] Banchereau, J. and Steinman, R.M. (1998) Nature 392, 245^
252.
[27] Steinman, R.M., Pack, M. and Inaba, K. (1997) Immunol. Rev.
156, 25^37.
[28] Cella, M., Sallusto, F. and Lanzavecchia, A. (1997) Curr. Opin.
Immunol. 9, 10^16.
[29] Caux, C., Liu, Y.J. and Banchereau, J. (1995) Immunol. Today
16, 2^4.
[30] Van Kooten, C. and Banchereau, J. (1997) Curr. Opin. Immunol.
9, 330^337.
[31] Hsieh, C.S., Macatonia, S.E., Tripp, C.S., Wolf, S.F., O’Garra,
A. and Murphy, K.M. (1993) Science 260, 547^549.
[32] Trinchieri, G. (1994) Immunol. Today 10, 460^464.
[33] Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lan-
zavecchia, A. and Alber, G. (1996) J. Exp. Med. 184, 747^752.
[34] Kalinski, P., Hilkens, C.M., Wierenga, E.A. and Kapsenberg,
M.L. (1999) Immunol. Today 20, 561^567.
[35] Sornasse, T., Flamand, V., De Becker, G., Bazin, H., Tielemans,
F., Thielemans, K., Urbain, J., Leo, O. and Moser, M. (1992)
J. Exp. Med. 175, 15^21.
[36] Bishop-Bailey, D. and Hla, T. (1999) J. Biol. Chem. 274, 17042^
17048.
[37] Chattopadhyay, N., Singh, D.P., Heese, O., Godbole, M.M.,
Sinohara, T., Black, P.M. and Brown, E.M. (2000) J. Neurosci.
Res. 61, 67^74.
[38] Thuillier, P., Baillie, R., Sha, X. and Clarke, S.D. (1998) J. Lipid
Res. 39, 2329^2338.
[39] Tineke, C.T., van der Pouw Kraan, M., Boeije, L.C., Smeenk,
R.J., Wijdenes, J. and Aarden, L. (1995) J. Exp. Med. 181, 775^
779.
[40] Kalinski, P., Hilkens, C.M., Snijders, A., Snijdewint, F.G. and
Kapsenberg, M.L. (1997) Adv. Exp. Med. Biol. 417, 363^367.
[41] Murphy, T.L., Cleveland, M.G., Kuleszka, P., Magram, J. and
Murphy, K.M. (1995) Mol. Cell. Biol. 15, 5258^5267.
[42] Straus, D.S., Pascual, G., Li, M., Welch, J.S., Ricote, M.,
Hsiang, C.H., Sengchanthalangsy, L.L., Ghosh, G. and Glass,
C.K. (2000) Proc. Natl. Acad. Sci. USA 97, 4844^4849.
[43] Marx, N., Mach, F., Sauty, A., Leung, J.H., Sara¢, M.N., Ran-
soho¡, R.M., Libby, P., Plutzky, J. and Luster, A.D. (2000)
J. Immunol. 164, 6503^6508.
FEBS 24411 11-12-00
C. Faveeuw et al./FEBS Letters 486 (2000) 261^266266
